Spotlight On... WuXi and PRA canceling joint venture in China; Recipharm to manufacture LIDDS drug; Perrigo adds Retin-A portfolio; and more...

With WuXi PharmaTech concentrating on manufacturing and PRA Health Sciences ($PRAH) developing its own global strategy, the two companies have decided to split up their China-focused joint venture. Instead, they will have an alliance but will divide their operations in the country after more than two years of collaboration. Story

> Sweden's Recipharm will invest SEK 5 million in LIDDS as part of an agreement for the contract manufacturer to scale up for commercial production of LIDDS treatment candidate for prostate cancer. Release

> Perrigo ($PRGO) has reacquired a portfolio of generic Retin-A (tretinoin) products from Matawan Pharmaceuticals. Release

> Pharma's price-gouging poster boy Martin Shkreli was arrested by the FBI Thursday. Story